Data gathered: September 17
Alternative Data for Kymera Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 12,000 | Sign up | Sign up | Sign up |
| Google Trends | 9 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 6 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 715 | Sign up | Sign up | Sign up |
| Twitter Mentions | N/A | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
About Kymera Therapeutics
Kymera Therapeutics, Inc., a biopharmaceutical company, is focused on discovering and developing new small molecule treatments that selectively break down disease-causing proteins by harnessing the body's own natural protein breakdown system. The company is headquartered in Watertown, Massachusetts.
| Price | $49.81 |
| Target Price | Sign up |
| Volume | 570,610 |
| Market Cap | $3.38B |
| Year Range | $21.05 - $49.81 |
| Dividend Yield | 0% |
| Analyst Rating | 75% buy |
| Industry | Biotechnology |
In the news
 |
Kymera Therapeutics to present on KT-621 at EADV CongressSeptember 17 - Thefly.com |
Kymera Therapeutics Announces Late-Breaking Oral Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader, at the European Academy of Dermatology & Venereology and European Respiratory Society CongressesSeptember 17 - GlobeNewswire |
|
 |
Kymera Therapeutics (NASDAQ:KYMR) Coverage Initiated at Royal Bank Of CanadaSeptember 16 - ETF Daily News |
 |
Kymera Therapeutics initiated with bullish view at Barclays, here's whySeptember 16 - Thefly.com |
|
Kymera Therapeutics initiated with bullish view at BarclaysSeptember 16 - Thefly.com |
|
Kymera Therapeutics initiated with bullish view at RBC Capital, here's whySeptember 16 - Thefly.com |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q2 '25 | 11M | 2.1M | 9.4M | -77M | -85M | -0.950 |
| Q1 '25 | 22M | 2M | 22M | -66M | -63M | -0.820 |
| Q4 '24 | 7.4M | 2M | 7.4M | -71M | -69M | -0.890 |
| Q3 '24 | 3.7M | 2M | 3.7M | -62M | -60M | -0.820 |
| Q2 '24 | 26M | 1.9M | 26M | -42M | -40M | -0.580 |
Insider Transactions View All
| Mainolfi Nello filed to sell 660,482 shares at $49. September 16 '25 |
| BIOTECHNOLOGY VALUE FUND L P filed to buy 353,412 shares at $44. July 1 '25 |
| BAKER JULIAN filed to buy 974,192 shares at $44. June 30 '25 |
| BIOTECHNOLOGY VALUE FUND L P filed to buy 2,219,858 shares at $44. July 1 '25 |
| BIOTECHNOLOGY VALUE FUND L P filed to buy 2,798,795 shares at $44. July 1 '25 |
Similar companies
Read more about Kymera Therapeutics (KYMR) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, sentiment, webpage traffic, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter mentions, news mentions & customer reviews.
What is the Market Cap of Kymera Therapeutics?
The Market Cap of Kymera Therapeutics is $3.38B.
What is the current stock price of Kymera Therapeutics?
Currently, the price of one share of Kymera Therapeutics stock is $49.81.
How can I analyze the KYMR stock price chart for investment decisions?
The KYMR stock price chart above provides a comprehensive visual representation of Kymera Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Kymera Therapeutics shares. Our platform offers an up-to-date KYMR stock price chart, along with technical data analysis and alternative data insights.
Does KYMR offer dividends to its shareholders?
As of our latest update, Kymera Therapeutics (KYMR) does not offer dividends to its shareholders. Investors interested in Kymera Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Kymera Therapeutics?
Some of the similar stocks of Kymera Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.